As Algeta's sibling, can Nordic Nanovector find the same success?

Privately held cancer drug developer Nordic Nanovector – a spin-out company from the same founders who built Xofigo creator Algeta – is raising NOK150m ($25m) through a private placement of shares in order to progress development of its early-stage-blood cancer radio-immunotherapy, Betalutin. The CEO told Scrip that if all goes well, the company hopes to find a strategic partner and launch an IPO next year. However, there is a lot still to prove.

Privately held cancer drug developer Nordic Nanovector – a spin-out company from the same founders who built Xofigo creator Algeta – is raising NOK150m ($25m) through a private placement of shares in order to progress development of its early-stage-blood cancer radio-immunotherapy, Betalutin. The CEO told Scrip that if all goes well, the company hopes to find a strategic partner and launch an IPO next year. However, there is a lot still to prove.

Betalutin is similar in its mode of action to Bayer/Spectrum Pharmaceuticals' CD20-targeting MAb Zevalin (ibritumomab tiuxetan), which is already approved...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Quick Listen: Scrip’s Five Must-Know Things

16 Jun 2025

• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

13 Jun 2025

• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

13 Jun 2025

• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

BioNTech To Buy mRNA Rivals CureVac

12 Jun 2025

• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

12 Jun 2025

• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.